Premium
Combination therapy for multiple myeloma
Author(s) -
Alexanian Raymond,
Salmon Sydney,
Bonnet John,
Gehan Edmund,
Haut Arthur,
Weick James
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197712)40:6<2765::aid-cncr2820400602>3.0.co;2-x
Subject(s) - medicine , vincristine , prednisone , cyclophosphamide , melphalan , carmustine , chemotherapy , multiple myeloma , oncology , maintenance therapy , radiation therapy , surgery
The effect of six different chemotherapy regimens were evaluated in 462 previously untreated patients with multiple myeloma. In comparison with other treatments, drug combinations that included vincristine and were given at 3‐week intervals were associated with higher response rates and longer survival times. No gain was noted from the use of Adriamycin or from combinations of alkylating agents unless vincristine was given and the treatment intervals were short. Seventy‐one responding patients were allocated at random to maintenance treatment with intermittent courses of either azathioprine‐prednisone or a combination of melphalan‐cyclophosphamide‐carmustine (BCNU)‐prednisone. The survival time was not prolonged with either maintenance treatment in comparison with that for responding patients continued on other therapies or on no therapy in previous studies. Attempts to reduce tumor mass maximally with a change in the therapeutic modality, such as with immunotherapy or radiotherapy, remain to be evaluated. Cancer 40:2765‐2771, 1977.